Compare CLDT & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLDT | HELP |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | Canada |
| Employees | 16 | 50 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 597.5M | 504.6M |
| IPO Year | N/A | N/A |
| Metric | CLDT | HELP |
|---|---|---|
| Price | $12.59 | $11.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $11.00 | ★ $51.50 |
| AVG Volume (30 Days) | 328.6K | ★ 1.9M |
| Earning Date | 05-07-2026 | 07-01-2026 |
| Dividend Yield | ★ 4.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.94 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $610.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.08 | $3.76 |
| 52 Week High | $13.88 | $11.48 |
| Indicator | CLDT | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | 83.33 |
| Support Level | $6.53 | $4.41 |
| Resistance Level | $13.76 | N/A |
| Average True Range (ATR) | 0.41 | 0.67 |
| MACD | -0.09 | 0.27 |
| Stochastic Oscillator | 12.37 | 91.47 |
Chatham Lodging Trust is a U.S.-based real estate investment trust that invests in upscale extended-stay hotels. The firm operates across various states in the U.S., including California, New York, Texas, Florida, Minnesota, Massachusetts, and Pennsylvania, among others. Substantially all of the company's assets are held and operated by its operating partnership, Chatham Lodging, LP. Chatham Lodging LP and its subsidiaries lease the overall company's hotels. Chatham's revenue streams include room, food and beverage, and other. The room comprises the majority of its total revenue. Chatham's hotels operate under various brands, which include Hilton, Marriott, and Hyatt.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.